Page last updated: 2024-12-08

1,2-dihexanoylglycerol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

## 1,2-Dihexanoylglycerol: A Key Player in Fat Metabolism

1,2-dihexanoylglycerol (1,2-DiC6:0) is a **diacylglycerol (DAG)**, a type of lipid molecule that plays a crucial role in fat metabolism and cellular signaling. It is specifically composed of two **hexanoic acid** (caproic acid) molecules attached to a glycerol backbone.

Here's why it's important for research:

**1. Understanding Fat Metabolism:**

* **Intermediate in triglyceride synthesis:** 1,2-DiC6:0 is a crucial intermediate in the biosynthesis of triglycerides, the primary form of fat storage in the body. Understanding its role helps researchers explore pathways for controlling fat storage and preventing obesity.
* **Potential for drug development:** Exploring the enzymatic pathways involving 1,2-DiC6:0 could lead to the development of new drugs that target specific steps in fat metabolism, potentially impacting lipid disorders and obesity treatment.

**2. Signaling Pathways:**

* **Activator of protein kinase C (PKC):** 1,2-DiC6:0 is a potent activator of protein kinase C (PKC), a family of enzymes crucial for various cellular processes, including cell growth, differentiation, and survival. This signaling pathway is involved in insulin sensitivity, glucose metabolism, and inflammation.
* **Investigating PKC activation:** Researchers use 1,2-DiC6:0 to investigate the mechanisms of PKC activation and its role in different diseases. This knowledge helps develop targeted therapies for various conditions, including cancer and diabetes.

**3. Studying Lipid Droplet Dynamics:**

* **Lipase activity:** 1,2-DiC6:0 is a substrate for specific lipases, enzymes that break down triglycerides stored in lipid droplets. Studying its breakdown helps researchers understand lipid droplet dynamics and their role in energy metabolism.
* **Targeting lipid droplet formation:** The study of 1,2-DiC6:0 may reveal new ways to target lipid droplet formation and mobilization, impacting various metabolic diseases and conditions like fatty liver disease.

**Overall, 1,2-dihexanoylglycerol is an important molecule for research as it offers insights into fat metabolism, signaling pathways, and lipid droplet dynamics. Further investigation could lead to groundbreaking discoveries in the treatment of various metabolic diseases and conditions.**

1,2-dihexanoylglycerol: functions as bioregulator of protein kinase C in human platelets; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID152222
CHEBI ID177077
SCHEMBL ID2195274
MeSH IDM0129508

Synonyms (16)

Synonym
CHEBI:177077
1,2-dicaproylglycerol
1,2-dimyristoyl-rac-glycerol, ~99%
1,2-dihexanoylglycerol
(2-hexanoyloxy-3-hydroxypropyl) hexanoate
33774-66-2
hexanoic acid, diester with 1,2,3-propanetriol
hexanoic acid, 1-(hydroxymethyl)-1,2-ethanediyl ester
17598-91-3
(2-hexanoyloxy-3-hydroxy-propyl) hexanoate
SCHEMBL2195274
2-(hexanoyloxy)-1-(hydroxymethyl)ethyl hexanoate
DTXSID30938726
3-hydroxypropane-1,2-diyl dihexanoate
PD049809
1-(hexanoyloxy)-3-hydroxypropan-2-yl hexanoate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
1,2-diglyceride
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (27.27)18.7374
1990's5 (45.45)18.2507
2000's3 (27.27)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]